Insulin Resistance: What Your Blood Tests Can Reveal

What is insulin resistance?

Think of insulin as a key, and the cells of your body as doors with locks. When you eat, blood sugar rises and your pancreas releases insulin. Insulin binds to receptors on your cells, unlocking them so glucose can enter and be used as energy.

Insulin resistance occurs when those locks start to malfunction. Your cells become less responsive to insulin's signal, so glucose stays in the bloodstream longer than it should. The pancreas compensates by producing more and more insulin — working harder to achieve the same result.

For a period of time, this compensation is effective. Blood glucose levels may appear normal while insulin levels quietly climb. But the pancreas cannot sustain this effort indefinitely. Over time, compensatory capacity declines, glucose regulation deteriorates, and the risk of developing prediabetes and eventually type 2 diabetes increases.

This is why insulin resistance is often called a silent condition. It develops across a continuum — sometimes over a decade or more — with no obvious symptoms in the early stages. By the time fasting glucose or HbA1c become abnormal, the underlying insulin dysfunction has typically been present for years.

Why insulin resistance matters for your health

Insulin resistance is not an isolated metabolic problem. It sits at the centre of a cluster of conditions that collectively represent significant health risk.

More than 1.3 million Australians — approximately 1 in 20 — were living with diabetes in 2021 (AIHW, 2024). Type 2 diabetes, which represents 85–90% of all cases, is strongly linked to insulin resistance (Diabetes Australia, 2024). An estimated 2 million Australians have prediabetes, and the majority are unaware of it.

Beyond blood sugar, metabolic syndrome — a cluster of conditions including elevated blood pressure, high triglycerides, low HDL cholesterol, abdominal obesity, and insulin resistance — affects up to 1 in 3 Australian adults (Healthdirect, 2024). Each component adds to cardiovascular risk; together, they substantially increase the risk of heart disease, stroke, and type 2 diabetes.

Insulin resistance is also closely associated with:

• Non-alcoholic fatty liver disease (NAFLD) — excess insulin promotes fat storage in the liver, contributing to liver inflammation over time
• Polycystic ovary syndrome (PCOS) — insulin resistance is a co-occurring condition and contributing factor in many women with PCOS (Jean Hailes, 2024)
• Cardiovascular disease — chronically elevated insulin levels contribute to inflammation, arterial stiffness, and dyslipidaemia
• Gestational diabetes — almost 1 in 5 women who gave birth in 2021–22 was diagnosed with gestational diabetes (AIHW, 2024), with pre-existing insulin resistance a significant risk factor

Understanding where you sit on this continuum — before clinical thresholds are crossed — is where blood testing has real value.

Key blood test biomarkers for insulin resistance

No single test definitively diagnoses insulin resistance. Instead, a pattern of markers — interpreted together — provides a meaningful picture. Below are the most informative biomarkers, with Australian reference ranges and units.

1. Fasting Insulin

[Fasting insulin](/blogs/biomarker-pages/fasting-insulin) measures how much insulin your pancreas is producing at rest, with no recent food intake. Elevated fasting insulin is often the earliest detectable sign that your cells are becoming resistant — the pancreas is working overtime to compensate.

In Australian pathology, fasting insulin is measured in µU/mL (or mIU/L, numerically equivalent). A general reference range used in clinical practice is approximately 3–17 µU/mL for fasting adults, though laboratory-specific ranges vary. Levels persistently above 10–12 µU/mL in a fasting state warrant discussion with your GP, even when fasting glucose appears normal.

Because fasting insulin is not routinely ordered in standard blood panels, many people with elevated levels go undetected for years.

2. Fasting Glucose

[Fasting glucose](/blogs/biomarker-pages/fasting-glucose) measures blood sugar levels after at least 8 hours without food. It is one of the standard diagnostic markers for prediabetes and type 2 diabetes.

Australian diagnostic thresholds (RACGP, 2024):

• Normal: below 5.5 mmol/L
• Impaired fasting glucose (prediabetes range): 5.5–6.9 mmol/L
• Consistent with diabetes: 7.0 mmol/L or above (requires confirmation)

A fasting glucose in the 5.5–6.9 mmol/L range does not confirm insulin resistance on its own — but combined with elevated fasting insulin, it is clinically significant. Fasting glucose also has a critical limitation: it may appear normal while insulin resistance is already well established, because the pancreas is successfully compensating.

3. HbA1c (Glycated Haemoglobin)

[HbA1c](/blogs/biomarker-pages/haemoglobin-a1c) reflects your average blood glucose level over the preceding 2–3 months. Because red blood cells carry sugar in proportion to ambient glucose, HbA1c provides a sustained snapshot rather than a point-in-time reading.

Australian thresholds (RACGP, 2024):

• Normal: below 5.7% (below 39 mmol/mol)
• Prediabetes range: 5.7–6.4% (39–47 mmol/mol)
• Consistent with diabetes: 6.5% or above (48 mmol/mol or above, requires confirmation)

HbA1c is reported in both % and mmol/mol in Australian pathology. It is a useful adjunct to fasting glucose but shares the same limitation — it can remain within range during the early phase of insulin resistance when compensation is still effective.

4. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)

HOMA-IR is a calculated index derived from fasting insulin and fasting glucose. The formula is: fasting insulin (µU/mL) × fasting glucose (mmol/L) ÷ 22.5.

It is not a standalone laboratory test — it is calculated from results you already have. A HOMA-IR below 1.0 is generally considered insulin-sensitive. Values between 1.5 and 2.5 suggest early or mild insulin resistance in many clinical references, and values above 2.5 are considered indicative of significant insulin resistance, though thresholds vary across studies and clinical guidelines.

HOMA-IR has limitations: it is most reliable in non-diabetic populations and does not replace formal glucose tolerance testing when clinical concern is high. Discuss interpretation with your GP.

5. Triglycerides

[Triglycerides](/blogs/biomarker-pages/triglycerides) are fat molecules that circulate in the blood. Insulin plays a key role in fat metabolism — insulin resistance impairs this process, leading to elevated triglyceride production by the liver.

In Australian pathology, triglycerides are measured in mmol/L. Desirable levels are below 1.7 mmol/L. Levels between 1.7 and 5.6 mmol/L are considered borderline to high; above 5.6 mmol/L is very high (RCPA). Fasting triglycerides above 1.7 mmol/L in combination with other markers are a useful signal of metabolic dysfunction.

The triglyceride-to-HDL ratio (TG:HDL) is also used by some clinicians as a surrogate marker for insulin resistance. A ratio above 1.8 (in mmol/L) has been associated with insulin resistance in several studies, though this is not a formally validated diagnostic threshold.

6. hs-CRP (High-Sensitivity C-Reactive Protein)

[hs-CRP](/blogs/biomarker-pages/high-sensitivity-c-reactive-protein-hs-crp) is a marker of systemic inflammation. Insulin resistance and visceral adiposity both drive low-grade chronic inflammation, which in turn worsens insulin sensitivity — a self-reinforcing cycle.

hs-CRP is measured in mg/L. For cardiovascular risk stratification, levels below 1.0 mg/L are considered low risk, 1.0–3.0 mg/L intermediate, and above 3.0 mg/L elevated risk. Persistently elevated hs-CRP in the context of other metabolic markers adds useful context when assessing overall metabolic health status.

What your results might mean

Interpreting these markers requires context — not just a single number. A result at the high end of the reference range is not the same as a confirmed diagnosis, and one abnormal result is not sufficient to conclude you have insulin resistance.

That said, patterns are meaningful:

• Elevated fasting insulin with normal fasting glucose — a classic early pattern. Your pancreas is compensating effectively, but the demand is higher than it should be. This is often the stage where lifestyle factors have the most influence.
• Fasting glucose in the impaired range (5.5–6.9 mmol/L) with elevated HOMA-IR — suggests the compensatory mechanism is beginning to strain. Your GP may discuss further testing, including an oral glucose tolerance test.
• HbA1c in the prediabetes range (5.7–6.4%) — sustained average glucose elevation. Combined with elevated fasting insulin or HOMA-IR, this is a clear signal to discuss next steps with your healthcare provider.
• High triglycerides + low HDL — a lipid pattern strongly associated with insulin resistance and metabolic syndrome. If you see fasting triglycerides above 1.7 mmol/L alongside HDL below 1.0 mmol/L (men) or 1.3 mmol/L (women), this combination warrants clinical attention.
• Elevated hs-CRP alongside metabolic markers — suggests the inflammatory component of insulin resistance is active.

None of these patterns constitute a diagnosis. Blood test results provide data — a clinician provides interpretation in the context of your full history, symptoms, and other investigations. Always discuss results with your GP before drawing conclusions or making significant changes.

Understand your metabolic health

Listen Health's annual membership includes fasting glucose, HbA1c, fasting insulin, a full lipid panel, and hs-CRP — the core biomarkers for tracking metabolic health over time. All testing is through accredited Australian pathology laboratories.

Start Testing Today

Developed by leading doctorsNo waiting, no referrals2,000+ locations Australia-wide

Risk factors and who should consider testing

Insulin resistance develops in response to a combination of genetic predisposition, lifestyle factors, and other medical conditions. Certain groups have meaningfully higher risk.

Consider discussing comprehensive metabolic testing with your GP if you have:

• A family history of type 2 diabetes — first-degree relatives with type 2 diabetes significantly increase your risk
• PCOS — insulin resistance is a co-occurring condition in a substantial proportion of women with PCOS, and metabolic testing is often part of PCOS workup
• A history of gestational diabetes — women who develop gestational diabetes have an increased long-term risk of type 2 diabetes and insulin resistance
• Abdominal obesity — visceral fat (fat stored around the organs) is metabolically active and strongly associated with insulin resistance; waist circumference above 94 cm in men and 80 cm in women is associated with increased metabolic risk
• A sedentary lifestyle — physical inactivity reduces insulin sensitivity; skeletal muscle is the primary site of insulin-mediated glucose disposal
• Age 45 or above — insulin sensitivity naturally declines with age; the RACGP recommends diabetes risk assessment for adults aged 40 and over every three years
• Aboriginal or Torres Strait Islander background — diabetes prevalence is 2.9 times higher in Aboriginal and Torres Strait Islander peoples compared to non-Indigenous Australians (AIHW, 2024); earlier and more frequent screening is recommended
• Previous impaired fasting glucose or HbA1c in the prediabetes range — regular monitoring is important to track whether levels are stable or progressing

Being in one of these groups does not mean you have insulin resistance. It means the data from comprehensive testing is more likely to be actionable, and earlier detection may open more options.

What you can do about it

If your results suggest early signs of insulin resistance, there is good evidence that lifestyle factors may help improve insulin sensitivity. These conversations belong with your GP, who can guide you based on your individual results and circumstances.

The evidence base most consistently supports:

• Regular physical activity — both aerobic exercise and resistance training are associated with improved insulin sensitivity; current Australian guidelines recommend at least 150 minutes of moderate-intensity activity per week
• Dietary patterns — diets lower in refined carbohydrates, higher in fibre, and emphasising whole foods are associated with better glucose regulation; your GP or an accredited practising dietitian can provide personalised guidance
• Weight management — even modest reductions in body weight (5–10%) may improve insulin sensitivity in people who are overweight; this should be approached through sustainable changes, not crash restriction
• Sleep — sleep deprivation is associated with reduced insulin sensitivity and impaired glucose regulation; consistent, adequate sleep is a modifiable factor that is often underestimated
• Stress management — chronic psychological stress elevates cortisol, which raises blood glucose and can reduce insulin sensitivity over time

These factors are worth discussing with your GP — what the evidence supports at a population level may not be the right starting point for your specific situation. Medications such as metformin are also used in clinical practice for prediabetes management; whether that applies to you is a decision for your healthcare provider, not a self-guided one.

Why regular testing matters

Insulin resistance develops on a continuum. A single blood test gives you a snapshot — a useful one, but limited. Serial testing over time tells a different story.

A fasting insulin that rises from 8 µU/mL one year to 14 µU/mL the next, while fasting glucose holds steady, is a pattern worth noting — even though both results may technically fall within reference ranges. It is the direction of travel that carries meaning.

Regular testing also provides a baseline you can share with your GP. When a clinical concern arises, a longitudinal record of your metabolic markers is far more informative than a single result taken in isolation. Your GP can see whether a current finding represents a new development or a continuation of a pre-existing trend.

The panel most useful for monitoring insulin resistance over time includes fasting insulin, fasting glucose, HbA1c, a full lipid panel (including triglycerides and HDL), and hs-CRP. Together, these markers cover the key metabolic, glycaemic, and inflammatory dimensions of insulin resistance.

For adults at higher risk — family history, PCOS, previous abnormal results, or age 45 and above — annual testing is reasonable. For lower-risk adults, testing every 1–3 years, consistent with RACGP guidance on diabetes risk assessment, may be appropriate. Discuss the right interval with your GP.